-
Mashup Score: 4
Introduction Lupus nephritis (LN) is more prevalent in patients with SLE of Asian ethnicity than in Caucasian patients. Belimumab became available in Japan in 2017 to treat patients with SLE, including those with LN. In the BLISS-LN trial ([NCT01639339][1]), belimumab showed a favourable effect on renal outcomes when combined with standard therapy (ST) starting at the induction treatment phase…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Objective SLE and lupus nephritis (LN) have significant impacts on the health-related quality of life of patients living with the condition, which are important to capture from the patient’s perspective using patient-reported outcomes (PROs). The objectives of this study were to evaluate the content validity of PROs commonly used in SLE and LN (36-Item Short Form Health Survey (SF-36), Functional…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Qualitative literature exploring the key #symptom and #HRQoL impact concepts important to #patients with #LN, confirming overlap in experiences and appropriateness of assessing the same concepts already identified by qualitative research in #SLE. https://t.co/dKtV1VlOMO
-
-
Mashup Score: 0
Background Complement activation has been associated with adverse pregnancy outcomes (APO) in SLE. Pregnant women with SLE were studied to evaluate whether complement dysregulation within the first two pregnancy trimesters predicts APO. Methods Pregnant women fulfilled classification criteria for SLE. APO included neonatal death, preterm delivery before 36 weeks and small for gestational age…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Identification of these early #biomarkers supports consideration of closer #management and reinforcement of already recommended preventive strategies, such as use of #aspirin and #hydroxychloroquine in #pregnant #patients with #SLE. https://t.co/s87rw9MLha
-
-
Mashup Score: 2
Introduction Lupus nephritis (LN) is more prevalent in patients with SLE of Asian ethnicity than in Caucasian patients. Belimumab became available in Japan in 2017 to treat patients with SLE, including those with LN. In the BLISS-LN trial ([NCT01639339][1]), belimumab showed a favourable effect on renal outcomes when combined with standard therapy (ST) starting at the induction treatment phase…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Postmarketing #study & #Lupus #Registry of #Nationwide Institutions, the #MOONLIGHT study explore effectiveness of #belimumab + ST by examining risk reduction in renal flare, ability to taper #corticosteroid treatment & #systemic responsiveness 3yrs after https://t.co/YGbo8x8WEs
-
-
Mashup Score: 0Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study - 2 year(s) ago
Objective To evaluate the risk of major infections and the relationship between major infections and mortality in patients with newly diagnosed SLE. Methods A newly diagnosed (<3 months) hospitalised Systemic Lupus Inception Cohort (hSLIC) in our centre during 1 January 2013 and 1 November 2020 was established. All patients were followed up for at least 1 year or until death. Patient baseline...
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Underlying profound #immune #disturbance is probably the reason that makes newly #onset active #SLE susceptible to major #infections, using appropriate #prediction #tool to identify #high-risk patients might lead to better #management & better #outcome. https://t.co/TDCW5I6D6u
-
-
Mashup Score: 1
Objective This retrospective analysis evaluated the prognostic value of renal response status 2 years after biopsy-proven lupus nephritis (LN) for the prediction of long-term renal outcomes. Methods Eligible patients with SLE as per American College of Rheumatology or Systemic Lupus International Collaborating Clinics criteria and biopsy-proven class III, IV, V or mixed LN were identified from…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Achieving a modified #primary efficacy #renal #response is significantly associated with better long-term renal #survival and #chronic renal #insufficiency-free survival in #patients with #LN. #SLE #Lupus https://t.co/7F9o118Nk3
-
-
Mashup Score: 0
Objective SLE and lupus nephritis (LN) have significant impacts on the health-related quality of life of patients living with the condition, which are important to capture from the patient’s perspective using patient-reported outcomes (PROs). The objectives of this study were to evaluate the content validity of PROs commonly used in SLE and LN (36-Item Short Form Health Survey (SF-36), Functional…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Qualitative literature exploring the key #symptom and #HRQoL impact concepts important to #patients with #LN, confirming overlap in experiences and appropriateness of assessing the same concepts already identified by qualitative research in #SLE. https://t.co/dKtV1VlOMO
-
-
Mashup Score: 0Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus - 2 year(s) ago
Objectives Numerous case reports have referred to new onset or flare of SLE after SARS-CoV-2 messenger RNA (mRNA) vaccines. Several observational studies showed that the short-term flare rate of SLE after SARS-CoV-2 vaccination is low. However, well-controlled clinical surveys are unavailable and the medium-term impact of the SARS-CoV-2 mRNA vaccines against the flare of SLE is uncertain….
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Using matched pair methods, #SARS-CoV-2 mRNA #vaccination was found not to influence the medium-term subjective and objective #disease activities or flares compared with those of the SARS-CoV-2 #mRNA #vaccinated and #unvaccinated control groups #SLE #lupus https://t.co/r8B8fqZpoq
-
-
Mashup Score: 0
Objective This retrospective analysis evaluated the prognostic value of renal response status 2 years after biopsy-proven lupus nephritis (LN) for the prediction of long-term renal outcomes. Methods Eligible patients with SLE as per American College of Rheumatology or Systemic Lupus International Collaborating Clinics criteria and biopsy-proven class III, IV, V or mixed LN were identified from…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
Achieving a modified #primary efficacy #renal #response is significantly associated with better long-term renal #survival and #chronic renal #insufficiency-free survival in #patients with #LN. #SLE #Lupus https://t.co/7F9o118Nk3
-
-
Mashup Score: 0Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis - 2 year(s) ago
Objectives Based on available data, the histological predictors of long-term outcome of lupus nephritis (LN) are not clearly defined. Aims of this retrospective study were: (i) to evaluate the change of chronicity index from the first to second kidney biopsy and to find the predictors of chronicity index increase and (ii) to detect the clinical/histological features at first and at second kidney…
Source: Lupus Science & MedicineCategories: Latest Headlines, RheumatologyTweet-
For the first time, the changes in chronicity index (CI) from 1st to 2nd #kidney #biopsy & looked for the predictors of CI increase in #LN Histological features at 1st and 2nd biopsy were tested as predictors of kidney #failure #lupus #lupusnephritis https://t.co/5ZuK41BMuo
-
Postmarketing #study & #Lupus #Registry of #Nationwide Institutions, the #MOONLIGHT study explore effectiveness of #belimumab + ST by examining risk reduction in renal flare, ability to taper #corticosteroid treatment & #systemic responsiveness 3yrs after https://t.co/YGbo8x8WEs